Stem cell transplant shows promise for rare blood cancer patients
NCT ID NCT02844361
First seen Feb 12, 2026 · Last updated Apr 30, 2026 · Updated 11 times
Summary
This study compares a stem cell transplant to standard chemotherapy for people with high-risk Waldenström macroglobulinemia, a rare blood cancer. The goal is to see if the transplant helps patients live longer. The trial involved 70 participants in China and has already been completed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTRÖM MACROGLOBULINEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Shuhua Yi
Tianjin, 300020, China
Conditions
Explore the condition pages connected to this study.